Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Escitalopram, IPT-A, and rTMS in Adolescent Depression
NCT05945342Recruiting
- Sponsor
- First Affiliated Hospital, Zhejiang University School of Medicine
- Start
- Jan 2023
- Primary completion
- Dec 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Randomised, single-blind trial of escitalopram in major depressive disorder (MDD) (5 arms), sponsored by First Affiliated Hospital, Zhejiang University School of Medicine. Primary endpoints: Child Depression Rating Scale-Revised at 8 weeks, Beck Scale for Suicide Ideation at 8 weeks and 11 more. Started Jan 2023; status: recruiting.
02
Drugs
escitalopram
03
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on NCT05945342.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05945342.